tldrdailynews.com logo

Summit's Lung Cancer Drugs Show Mixed Results in Global Trials

1 min read
Source: Fierce Pharma
Summit's Lung Cancer Drugs Show Mixed Results in Global Trials
Photo: Fierce Pharma
TL;DR

Akeso and Summit Therapeutics' drug ivonescimab showed promising results in delaying progression of certain lung cancers in a global phase 3 trial, with significant improvements in progression-free survival, though overall survival benefits are still being evaluated. The drug demonstrated consistent effects across Asian and Western populations, and the companies plan to seek FDA approval, despite some investor disappointment over the overall survival data.

Topics:businesshealthcare#healthcare#ivonescimab#lung-cancer#nsclc#phase-3-trial#summit-therapeutics
Share this article
  1. Akeso, Summit's ivonescimab delayed progression of certain lung cancers in first global phase 3 readout  Fierce Pharma
  2. Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.  Barron's
  3. Summit shows mixed results from key study of lung cancer drug  statnews.com
  4. Ivonescimab Plus Chemo Meets PFS End Point in EGFR+ NSCLC After an EGFR TKI  OncLive
  5. Summit’s Bispecific Misses Survival Endpoint in Global Phase III Trial but Analysts Remain Optimistic  BioSpace

Want the full story? Read the original reporting

Read on Fierce Pharma